The production of chromosomal alterations by beta-lapachone, an activator of topoisomerase I

Mutat Res. 1993 Aug;288(2):263-7. doi: 10.1016/0027-5107(93)90093-u.

Abstract

The frequencies of chromosomal aberrations and sister-chromatid exchanges (SCE) after exposure to beta-lapachone, an activator of mammalian topoisomerase I, were studied in Chinese hamster cells. A dose-dependent increase in the frequencies of SCE was observed in continuous treatments with beta-lapachone. Chromatid-type aberrations were obtained in cells exposed to beta-lapachone for one cell cycle but also in cells exposed during the G2 phase of the cell cycle, with a marked induction of exchange-type aberrations for both treatment schedules. We therefore propose that activation of topoisomerase I by beta-lapachone results in the production of chromosomal alterations. The cell cycle dependence of beta-lapachone clastogenic effects strongly suggests a mechanism for the formation of chromosomal aberrations after this drug closely resembling the one observed for the topoisomerase I inhibitor, camptothecin.

MeSH terms

  • Animals
  • CHO Cells
  • Chromosome Aberrations*
  • Cricetinae
  • DNA Damage
  • DNA Topoisomerases, Type I / drug effects
  • DNA Topoisomerases, Type I / metabolism*
  • Enzyme Activation / drug effects
  • Naphthoquinones / toxicity*
  • Sister Chromatid Exchange / drug effects

Substances

  • Naphthoquinones
  • beta-lapachone
  • DNA Topoisomerases, Type I